Publications by authors named "Charlotte Fenioux"
Background And Aims: Immune checkpoint inhibitors (ICI) are associated with life-threatening myocarditis but milder presentations are increasingly recognized. The same autoimmune process that causes ICI myocarditis can manifest concurrent generalized myositis, myasthenia-like syndrome, and respiratory muscle failure. Prognostic factors for this 'cardiomyotoxicity' are lacking.
View Article and Find Full Text PDFPurpose: Using electronic patient-reported outcomes (ePRO) in clinical trial has shown benefits for patients. However, the digital divide can lead to unequal access to telehealth. We investigated whether a dedicated support program could bridge that divide.
View Article and Find Full Text PDFArticle Synopsis
- Immune-checkpoint inhibitors (ICIs) can lead to serious heart issues like myocarditis, which can also involve broader muscle-related symptoms, highlighting the need for understanding associated risks.
- A study conducted across 17 countries from 2014 to 2023 examined data from 748 patients to identify factors that predict severe outcomes related to these heart complications, using a statistical model for analysis.
- Key findings indicated that certain conditions (like active thymoma) and symptoms (like low heart function) significantly increased the risk of severe heart-related events, and a risk score created from these factors effectively predicted outcomes, validated in multiple cohorts.
Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases.
Clin J Am Soc Nephrol
July 2024
Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins.
View Article and Find Full Text PDFArticle Synopsis
- * Research shows that patients with thymic epithelial tumors (TET), especially thymoma, experience ICI-related myotoxicities more frequently and with greater severity than those with other cancers.
- * The presence of anti-acetylcholine-receptor antibodies suggests a link between thymic-related autoimmune responses and ICI myotoxicities, indicating that assessing the thymus could help predict these serious side effects in patients undergoing ICI therapy.
Background: Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent but life-threatening condition. Elevations in cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), are used for diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory and outcomes has not been established.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the connection between immune-checkpoint inhibitor (ICI)-associated myotoxicity, specifically looking at myocarditis and myositis, which can be life-threatening.
- It details a treatment strategy that involved the use of mechanical ventilation for respiratory muscle issues and the administration of the drugs abatacept and ruxolitinib in patients diagnosed with severe ICI myocarditis.
- Results showed a significant drop in myotoxicity-related fatalities from 60% in the initial patient group to just 3.4% in the later group, indicating the effectiveness of early intervention and specific treatment adjustments.
Article Synopsis
- ICB-myocarditis can mimic other heart issues like acute coronary syndrome, complicating quick diagnosis.
- A study of 261 patients revealed that 22.6% had coronary artery disease (CAD), with those undergoing revascularization having higher 90-day mortality rates.
- The presence of CAD alongside ICB-myocarditis can worsen outcomes, especially after revascularization, highlighting the need for careful diagnosis and management.
Importance: Patients with solid cancer are more susceptible to develop SARS-CoV-2 infection and severe complications; the immunogenicity in patients treated with anticancer agents remains unknown.
Objective: To assess the immune humoral response to 2 or 3 doses of the BNT162b2 (BioNTech; Pfizer) vaccine in patients treated with anticancer agents.
Design, Setting, And Participants: A prospective observational cohort study was conducted between February 1 and May 31, 2021.
Background: Patients with solid cancer or haematologic malignancies have been considered to be more susceptible to SARS-CoV-2 infection and to more often develop severe complications. We aimed to compare the differences in clinical features and outcomes of COVID-19 patients with and without cancer.
Methods: This was a prospective observational cohort study of consecutive adult patients hospitalised in a COVID-19 unit at Pitié-Salpêtrière Hospital, Paris, France (NCT04320017).
Immune checkpoint inhibitors (ICIs) have improved the management and the prognosis of patients with cancer but are associated with an increased risk of toxicities that can affect every organ. ICI-associated myocarditis has a low incidence (< 1%) but a high fatality rate (30%-50%). Herein we report a patient treated with ICI admitted for suspicion of myocarditis.
View Article and Find Full Text PDF• We summarised immunosuppressing anticancer drugs which could worsen COVID 19 infections. • Other drugs were studied for drug-drug interactions with antiviral medicines. • A ready-to-use table synthesised these interactions between antiviral and anticancer drugs.
View Article and Find Full Text PDFObjective: To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic prostate-specific antigen (PSA) progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).
Materials And Methods: Among 93 patients treated with AA between January 2013 and April 2016 in our institution, 48 consecutive asymptomatic patients with mCRPC, who experienced biochemical progression on treatment with AA+P 10 mg/day, were included. A corticosteroid switch to AA+D 0.